Longeveron (LGVN) AI Stock Analysis

• Market Cap: $19.38M
• Dividend Yield: N/A
• Average Volume (3M): 473.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.52
• Revenue Growth: 68.67%
• EPS Growth: 85.44%
• Country: US
• Employees: 25
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.33
• Shares Outstanding: 19,576,923
• 10 Day Avg. Volume: 706,553
• 30 Day Avg. Volume: 473,105
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 4.98
• Enterprise Value/Gross Profit: 6.32
• Enterprise Value/Ebitda: -0.55
• 1Y Price Target: $3.50
• Price Target Upside: 316.67% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 46 Neutral
• Price Target: $1.00 ▲(19.05% Upside)

Longeveron's overall stock score is primarily impacted by its poor financial performance, characterized by declining revenues and persistent losses. While there are positive developments in clinical trials and strategic initiatives, these are overshadowed by financial challenges and uncertainties. Technical indicators and valuation metrics also reflect a cautious outlook.

Positive Factors

Regulatory Progress

The pivotal status of ELPIS II by the FDA enhances Longeveron's regulatory pathway, potentially leading to faster approval and commercialization of laromestrocel, thus strengthening its market position in regenerative medicine.

Pipeline Expansion

Expanding the pipeline with new indications like pediatric dilated cardiomyopathy and securing FDA approval for trials indicates robust R&D capabilities, potentially leading to diversified revenue streams and long-term growth.

Strategic Manufacturing Partnership

Partnering with a third-party CDMO for manufacturing leverages external expertise and scalability, enhancing operational efficiency and readiness for potential product launches, supporting long-term strategic goals.

Negative Factors

Declining Revenue

A significant decline in revenue reflects challenges in market demand and operational execution, which could hinder financial stability and limit resources for future growth initiatives.

Increased Operational Expenses

Rising operational costs without corresponding revenue growth strain profitability and cash flow, potentially impacting the company's ability to invest in strategic initiatives and sustain operations long-term.

Leadership Changes

Frequent leadership changes can lead to strategic uncertainty and disrupt continuity in execution, potentially affecting stakeholder confidence and the company's ability to navigate industry challenges effectively.

Longeveron Business Overview & Revenue Model

Company Description

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

How the Company Makes Money

Longeveron generates revenue primarily through the development and commercialization of its cellular therapies. The company conducts clinical trials to advance its product candidates, which can lead to partnerships with larger pharmaceutical companies for further development and distribution. Additionally, Longeveron may receive funding through government grants or collaborations for research and development efforts. Key revenue streams include potential product sales from successful clinical trials, licensing agreements, and partnerships that may provide milestone payments and royalties based on future sales of its therapies.

Longeveron Financial Statement Overview

Summary

Longeveron faces significant financial challenges with declining revenues and persistent losses impacting profitability. Despite a high gross profit margin and low leverage, negative cash flows and return on equity highlight ongoing operational and financial difficulties.

Income Statement

Longeveron shows a declining revenue trend with a negative revenue growth rate of -6.83% in the TTM. The company has consistently negative net profit margins, indicating ongoing losses. Gross profit margins are relatively high at 78.77%, but the negative EBIT and EBITDA margins highlight significant operational challenges.

Balance Sheet

The company's debt-to-equity ratio is low at 0.05, indicating minimal leverage, which is a positive aspect. However, the return on equity is significantly negative at -95.90%, reflecting poor profitability relative to shareholder equity. The equity ratio stands at 75.57%, suggesting a strong equity base relative to total assets.

Cash Flow

Longeveron has negative operating cash flow and free cash flow, with a declining free cash flow growth rate of -8.43% in the TTM. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is close to 1, suggesting that cash flow is closely aligned with net income, albeit negative.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.07M	2.39M	709.00K	1.22M	1.31M	5.63M
Gross Profit	1.63M	1.88M	221.00K	497.00K	590.00K	1.83M
EBITDA	-18.61M	-15.56M	-20.06M	-17.15M	-16.18M	-2.93M
Net Income	-18.54M	-15.97M	-21.41M	-18.84M	-17.05M	-3.72M
Balance Sheet
Total Assets	16.75M	25.56M	12.08M	27.41M	42.77M	9.24M
Cash, Cash Equivalents and Short-Term Investments	10.33M	19.23M	5.36M	19.66M	35.04M	815.80K
Total Debt	639.00K	1.45M	2.04M	2.60M	3.14M	4.14M
Total Liabilities	4.09M	3.67M	5.34M	6.91M	5.31M	7.28M
Stockholders Equity	12.66M	21.89M	6.74M	20.50M	37.45M	1.96M
Cash Flow
Free Cash Flow	-14.27M	-14.86M	-19.70M	-14.82M	-10.95M	-2.63M
Operating Cash Flow	-14.51M	-13.87M	-19.00M	-13.97M	-9.64M	-2.36M
Investing Cash Flow	-1.01M	-640.00K	8.19M	-677.00K	-10.70M	-261.50K
Financing Cash Flow	13.48M	28.79M	5.26M	-509.00K	45.17M	1.58M

Longeveron Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.84
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LGVN, the sentiment is Negative. The current price of 0.84 is below the 20-day moving average (MA) of 0.84, above the 50-day MA of 0.81, and below the 200-day MA of 1.29, indicating a neutral trend. The MACD of 0.02 indicates Negative momentum. The RSI at 49.19 is Neutral, neither overbought nor oversold. The STOCH value of 69.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for LGVN.

Longeveron Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LGVN	―	$19.38M	-0.72	-134.50%	―	68.67%	85.44%
IBIO	―	$31.39M	-0.89	-101.52%	―	77.78%	84.08%
FBLG	―	$16.79M	―	―	―	―	43.68%
EDSA	―	$14.57M	-1.56	-69.64%	―	―	22.63%
CMMB	―	$15.42M	-1.26	-120.76%	―	―	47.86%
PCSA	―	$15.41M	―	-212.38%	―	―	57.99%

Longeveron Corporate Events

Longeveron Appoints Dr. George Paletta to Board

On October 1, 2025, Longeveron Inc. announced the appointment of Dr. George Paletta to its Board of Directors. Dr. Paletta, an internationally recognized orthopedic surgeon and entrepreneur, brings extensive experience in medicine and business to the company. His appointment comes at a pivotal time for Longeveron as it advances its stem cell therapy pipeline, including a pivotal clinical trial in hypoplastic left heart syndrome with data expected in 2026. This strategic addition is expected to enhance Longeveron’s efforts in commercializing stem cell therapies, benefiting healthcare, patients, and shareholders.

The most recent analyst rating on (LGVN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Faces Nasdaq Delisting Notice for Stock Price

On September 22, 2025, Longeveron Inc. received a notice from Nasdaq indicating that its Class A common stock failed to meet the $1.00 minimum bid price requirement for continued listing. The company has until March 23, 2026, to regain compliance by ensuring the bid price closes at $1.00 or more for at least ten consecutive business days. If compliance is not achieved, Longeveron may face delisting or seek an additional compliance period while assessing options to rectify the deficiency.

The most recent analyst rating on (LGVN) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Announces Leadership Changes Amidst CEO Departure

On August 27, 2025, Longeveron Inc. announced a leadership change with CEO Wa’el Hashad stepping down to pursue other opportunities. Than Powell, the current Chief Business Officer, was appointed as interim CEO effective September 4, 2025. Dr. Joshua Hare, the company’s founder and Chief Science Officer, was appointed as Executive Chairman of the Board. This transition occurs as Longeveron continues to advance its stem cell therapy pipeline, with pivotal Phase 2b clinical trials underway for laromestrocel, and plans for a national search to identify a permanent CEO. The company remains focused on leveraging its stem cell technology to benefit patients and shareholders.

The most recent analyst rating on (LGVN) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.

Longeveron Inc. Earnings Call: Progress Amid Challenges

Longeveron Inc.’s recent earnings call painted a mixed picture, highlighting significant strides in clinical trials and pipeline expansion, while also acknowledging challenges such as declining revenue and rising expenses. The sentiment was cautiously optimistic, with strategic moves in manufacturing and financial planning being tempered by regulatory and financial uncertainties.

Longeveron Inc. Faces Regulatory and Manufacturing Challenges Threatening Financial Stability

Longeveron Inc. faces significant business risks related to its CMC readiness and manufacturing capabilities for commercialization, which may experience delays or be unsuccessful. The complexity of BLA-enabling activities, such as comparability protocols and process validation, coupled with regulatory scrutiny, poses challenges that could impede the company’s ability to meet regulatory and investor expectations for product approval and launch. The FDA’s discretionary power and the uncertain, costly approval process further exacerbate these risks, potentially affecting the clinical and commercial success of Longeveron’s product candidates. Consequently, any setbacks in completing CMC readiness and BLA-enabling activities could materially harm Longeveron’s financial condition.

Longeveron Inc. Reports Q2 2025 Financial Results

Longeveron Inc. is a clinical stage biotechnology company focused on developing regenerative medicines for life-threatening, rare pediatric, and chronic aging-related conditions. The company recently announced its second quarter 2025 financial results and provided a business update, highlighting significant progress in its clinical trials and strategic initiatives.

Longeveron Closes $5 Million Public Stock Offering

On August 8, 2025, Longeveron announced the pricing of a public offering of its Class A common stock, which closed on August 11, 2025. The offering, managed by H.C. Wainwright & Co., is expected to generate approximately $5 million upfront, with an additional potential $12.5 million from short-term warrants. The proceeds will support the development of laromestrocel for various conditions and regulatory activities.

The most recent analyst rating on (LGVN) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Longeveron stock, see the LGVN Stock Forecast page.